Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism : results of the DIANA Study
Millán Núñez-Cortés, Jesús (Hospital General Universitario Gregorio Marañón)
Cases Amenós, Aleix (Hospital Clínic i Provincial de Barcelona)
Ascaso, Juan F (Hospital Clínic Universitari (València))
Barrios, Vivencio (Hospital Universitario Ramón y Cajal (Madrid))
Pascual Fuster, Vicente (Centro de Salud Palleter, Castellón, Spain)
Pedro-Botet Montoya, Juan Carles (Hospital del Mar (Barcelona, Catalunya))
Pintó, Xavier (Hospital Universitari de Bellvitge)
Serrano Cumplido, Adalberto (Centro de Salud de Repélega (Portugalete, País Basc))
Universitat Autònoma de Barcelona

Data:	2016
Resum:	Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.
Nota:	Altres ajuts: Laboratorios del Dr. Esteve, S.A.U. has supported the scientific committee to undertake the fieldwork of the Delphi survey for this study, without participating in the design, data analysis or drafting of this article
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Statins ; Diabetes ; Impaired glucose tolerance Consensus
Publicat a:	American Journal of Cardiovascular Drugs, Vol. 17 (november 2016) , p. 135-142, ISSN 1179-187X

DOI: 10.1007/s40256-016-0197-9
PMID: 27837448

8 p, 630.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats